TG Therapeutics (TGTX) reported a Q4 net income Monday of $0.15 per diluted share, swinging from loss of $0.10 a year earlier.
Analysts polled by FactSet expected earnings of $0.16.
Revenue for the quarter ended Dec. 31 was $108.2 million, up from $44 million a year earlier.
Analysts surveyed by FactSet expected $100.7 million.
The company said it expects full-year 2025 revenue of around $540 million. Analysts polled by FactSet expect $534.4 million.
As of Dec. 31, the company said it had $311 million in cash, cash equivalents and investment securities, which combined with the expected revenue from Briumvi, will be "sufficient" to fund the company's business based on its current operating plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.